Jinneng Science & Technology (603113.SH) releases a forecast for an expected net loss of 49-59 million RMB in the fiscal year 2024, which will result in a shift from profit to loss.
Golden Power Technology (603113.SH) issued an announcement, stating that the company is expected to achieve a net profit attributable to the listed company's shareholders for the fiscal year 2024...
Jinneng Science & Technology (603113.SH) announced that the company expects a net loss of 49-59 million yuan attributable to shareholders of the listed company in 2024. The company had a profit of 137 million yuan in the same period last year.
In 2024, due to the impact of the macroeconomic environment and weak demand in the downstream product market, the company's product gross profit level has declined, leading to a loss in annual profit. In the face of a challenging situation, the company will actively promote cost reduction and efficiency enhancement, fully leverage the competitive advantages of the industrial chain and product differentiation, and ensure the stable operation of the company's production and operation.
Related Articles

On September 16th, LIVZON PHARMA (01513) spent 3.6914 million yuan to repurchase 92,100 A-shares.

Jiangxi Synergy Pharmaceutical (300636.SZ) has obtained the European Pharmacopoeia Certification.

Shanghai Shyndec Pharmaceutical (600420.SH) : The Injection of Pentobarbital Sodium has obtained a drug registration certificate.
On September 16th, LIVZON PHARMA (01513) spent 3.6914 million yuan to repurchase 92,100 A-shares.

Jiangxi Synergy Pharmaceutical (300636.SZ) has obtained the European Pharmacopoeia Certification.

Shanghai Shyndec Pharmaceutical (600420.SH) : The Injection of Pentobarbital Sodium has obtained a drug registration certificate.
